Survey on PARP Inhibitors: Hello All The National... - OvaCare

OvaCare

2,038 members1,116 posts

Survey on PARP Inhibitors

Ovacare2 profile image
Ovacare2AdministratorOvaCare Team Member
0 Replies

Hello All

The National Centre for Pharmacoeconomics has completed a rapid review of olaparib for the treatment of ovarian cancer, as maintenance treatment following first line platinum-based chemotherapy . The conclusion of the rapid review is that a full Health Technology Assessment (HTA) is required, which the manufacturer has recently submitted. This is to assess the feasibility for reimbursement of the drug.

As part of the NCPE evaluation process, they welcome submissions from patient organisations. Ovacare are keen to submit to support the reimbursement of PARP inhibitors to be used in first line treatment as a maintenance drug.

To assist this we would welcome your input on this short survey. Apologies on the timing but we would appreciate your input by next Tue 7th Jan. Please see link below.

surveymonkey.com/r/F7LBLMN

Written by
Ovacare2 profile image
Ovacare2
Administrator
To view profiles and participate in discussions please or .
Read more about...

Not what you're looking for?

You may also like...

Up date on Parp inhibitor treatment

Saw my Onc yesterday who is happy with my treatment so far. Side effects so far are,chilly hands...

Hello All

I have just discovered this site and this is my first post attempt! I was recently diagnosed with...

Any ideas on fundraising for ovacare

As you can see by me writing this ,it's 3.40am still up and wide awake. I was wondering if there is...

UpDate on Olaparib

Had my check up on the 15th of September. All blood results are great,CA125 is down to 10! Fatigue...

cisplatin

Hi Ladies hope ye are all well as possible. I need some urgent replies as I think I must have the...